IREIT Global Valuation
Is 8U7U undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8U7U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8U7U (€0.21) is trading below our estimate of fair value (€0.72)
Significantly Below Fair Value: 8U7U is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8U7U?
Key metric: As 8U7U is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 8U7U's PS Ratio? | |
|---|---|
| PS Ratio | 3.6x |
| Sales | €73.18m |
| Market Cap | €266.68m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.7x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 8U7U's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
MXNU Elite UK REIT | 3.9x | -4.5% | UK£169.3m |
CMOU Keppel Pacific Oak US REIT | 1.5x | 0.1% | US$229.8m |
OXMU Prime US REIT | 1.4x | 2.0% | US$215.9m |
BTOU Manulife US Real Estate Investment Trust | 0.9x | -5.7% | US$179.4m |
8U7U IREIT Global | 3.6x | -10.9% | €376.6m |
Price-To-Sales vs Peers: 8U7U is expensive based on its Price-To-Sales Ratio (3.6x) compared to the peer average (1.9x).
Price to Sales Ratio vs Industry
How does 8U7U's PS Ratio compare vs other companies in the Asian Office REITs Industry?
| 0 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 8U7U is good value based on its Price-To-Sales Ratio (3.6x) compared to the Asian Office REITs industry average (6.5x).
Price to Sales Ratio vs Fair Ratio
What is 8U7U's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8U7U's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €0.25 0% | 9.2% | €0.27 | €0.23 | n/a | 2 |
| Nov ’25 | n/a | €0.25 0% | 9.2% | €0.27 | €0.23 | n/a | 2 |
| Oct ’25 | n/a | €0.25 0% | 9.2% | €0.27 | €0.23 | n/a | 2 |
| Sep ’25 | n/a | €0.25 0% | 9.2% | €0.27 | €0.23 | n/a | 2 |
| Aug ’25 | n/a | €0.29 0% | 5.0% | €0.30 | €0.27 | n/a | 2 |
| Jul ’25 | n/a | €0.31 0% | 3.0% | €0.32 | €0.30 | n/a | 2 |
| Jun ’25 | n/a | €0.31 0% | 3.0% | €0.32 | €0.30 | n/a | 2 |
| May ’25 | n/a | €0.31 0% | 3.0% | €0.32 | €0.30 | n/a | 2 |
| Apr ’25 | n/a | €0.31 0% | 3.0% | €0.32 | €0.30 | n/a | 2 |
| Mar ’25 | €0.26 | €0.31 +20.2% | 3.0% | €0.32 | €0.30 | n/a | 2 |
| Feb ’25 | n/a | €0.31 0% | 2.9% | €0.32 | €0.30 | n/a | 2 |
| Jan ’25 | n/a | €0.30 0% | 3.0% | €0.30 | €0.29 | n/a | 2 |
| Dec ’24 | n/a | €0.30 0% | 3.0% | €0.30 | €0.29 | n/a | 2 |
| Nov ’24 | n/a | €0.30 0% | 3.0% | €0.30 | €0.29 | n/a | 2 |
| Oct ’24 | n/a | €0.30 0% | 3.0% | €0.30 | €0.29 | n/a | 2 |
| Sep ’24 | n/a | €0.34 0% | 9.2% | €0.37 | €0.30 | n/a | 2 |
| Aug ’24 | n/a | €0.39 0% | 7.0% | €0.42 | €0.37 | n/a | 2 |
| Jul ’24 | n/a | €0.39 0% | 7.0% | €0.42 | €0.37 | n/a | 2 |
| Jun ’24 | €0.35 | €0.40 +13.7% | 6.0% | €0.42 | €0.37 | n/a | 2 |
| May ’24 | n/a | €0.40 0% | 6.0% | €0.42 | €0.37 | n/a | 2 |
| Apr ’24 | n/a | €0.40 0% | 4.6% | €0.42 | €0.39 | n/a | 2 |
| Mar ’24 | €0.36 | €0.40 +12.1% | 4.6% | €0.42 | €0.39 | €0.26 | 2 |
| Feb ’24 | €0.36 | €0.43 +19.2% | 2.1% | €0.44 | €0.43 | n/a | 2 |
| Jan ’24 | €0.34 | €0.43 +26.1% | 2.1% | €0.44 | €0.43 | n/a | 2 |
| Dec ’23 | n/a | €0.43 0% | 2.1% | €0.44 | €0.43 | n/a | 2 |
| Nov ’23 | €0.34 | €0.50 +44.5% | 2.7% | €0.51 | €0.48 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Cromwell European Real Estate Investment Trust
€916.7m
Cromwell European Real Estate Investment Trust (“Cromwell European REIT” or “CEREIT”) has a principal mandate to invest, directly or indirectly, in income-producing commercial real estate assets across Europe with a minimum portfolio weighting of at least 75% to Western Europe and at least 75% to the light industrial / logistics and office sectors.
CWBU
€1.63
7D
1.9%
1Y
23.5%
Acrophyte Hospitality Trust
US$107.3m
Listed on the Singapore Exchange on 9 May 2019, ARA US Hospitality Trust is a hospitality stapled group comprising ARA US Hospitality Property Trust (“ARA H-REIT”) and ARA US Hospitality Management Trust (“ARA H-BT”).
XZL
US$0.18
7D
-1.6%
1Y
-35.1%
Cromwell European Real Estate Investment Trust
€916.7m
Cromwell European Real Estate Investment Trust (“Cromwell European REIT” or “CEREIT”) has a principal mandate to invest, directly or indirectly, in income-producing commercial real estate assets across Europe with a minimum portfolio weighting of at least 75% to Western Europe and at least 75% to the light industrial / logistics and office sectors.
CWCU
€2.28
7D
0.4%
1Y
16.9%